PetMed Express, Inc. (PETS) 10-Year Financial Performance & Capital Metrics

PETS • • Industrial / General

HealthcarePharmaceuticalsSpecialty Pharmaceuticals & DistributionPet Pharmaceuticals

AboutPetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; telephone contact center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds and PetMeds brands. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.Show more

Revenue $227M -17.2%
EBITDA $6M +5760.6%
Net Income -$6M +16.0%
EPS (Diluted) -0.30 +18.9%
Gross Margin 30.46% +7.4%
EBITDA Margin 2.43% +6976.4%
Operating Margin -0.67% +73.5%
Net Margin -2.76% -1.5%
ROE -6.9% +4.5%
ROIC -3.09% +85.3%
Debt/Equity 0.01 -22.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.8x book value
✓Efficient asset utilization: 1.5x turnover

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-0.11%

5Y-4.39%

3Y-6.02%

TTM-24.81%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-5613.71%

EPS CAGR

10Y-

5Y-

3Y-

TTM-4383.61%

ROCE

10Y Avg22.94%

5Y Avg7.43%

3Y Avg-1.05%

Latest-1.67%

Peer Comparison

Pet Pharmaceuticals

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PETSPetMed Express, Inc.	72.66M	3.40	-11.33	-17.19%	-28.22%	-127.77%		0.01

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	234.68M	249.18M	273.8M	283.42M	284.13M	303.58M	273.42M	256.58M	274.1M	226.97M
Revenue Growth %	0.02%	0.06%	0.1%	0.04%	0%	0.07%	-0.1%	-0.06%	0.07%	-0.17%
Cost of Goods Sold+	158.39M	169.86M	175.99M	188.1M	202.88M	219.27M	198.08M	185.84M	196.38M	157.84M
COGS % of Revenue	0.67%	0.68%	0.64%	0.66%	0.71%	0.72%	0.72%	0.72%	0.72%	0.7%
Gross Profit+	76.3M	79.31M	97.81M	95.31M	81.25M	84.32M	75.34M	71.01M	77.71M	69.14M
Gross Margin %	0.33%	0.32%	0.36%	0.34%	0.29%	0.28%	0.28%	0.28%	0.28%	0.3%
Gross Profit Growth %	0%	0.04%	0.23%	-0.03%	-0.15%	0.04%	-0.11%	-0.06%	0.09%	-0.11%
Operating Expenses+	43.91M	41.83M	45.67M	49.14M	50.27M	53.78M	49.63M	64.68M	84.67M	70.67M
OpEx % of Revenue	0.19%	0.17%	0.17%	0.17%	0.18%	0.18%	0.18%	0.25%	0.31%	0.31%
Selling, General & Admin	43.14M	40.46M	43.55M	46.91M	48.01M	49.93M	49.63M	68.9M	79.75M	62.43M
SG&A % of Revenue	0.18%	0.16%	0.16%	0.17%	0.17%	0.16%	0.18%	0.27%	0.29%	0.28%
Research & Development	0	0	0	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	770K	1.37M	2.13M	2.23M	2.26M	3.85M	0	-4.21M	4.92M	8.24M
Operating Income+	32.39M	37.48M	52.14M	46.17M	30.98M	30.53M	25.71M	6.55M	-6.96M	-1.53M
Operating Margin %	0.14%	0.15%	0.19%	0.16%	0.11%	0.1%	0.09%	0.03%	-0.03%	-0.01%
Operating Income Growth %	0.17%	0.16%	0.39%	-0.11%	-0.33%	-0.01%	-0.16%	-0.75%	-2.06%	0.78%
EBITDA+	33.16M	38.85M	54.26M	48.4M	33.23M	32.96M	28.45M	10.1M	94K	5.51M
EBITDA Margin %	0.14%	0.16%	0.2%	0.17%	0.12%	0.11%	0.1%	0.04%	0%	0.02%
EBITDA Growth %	0.17%	0.17%	0.4%	-0.11%	-0.31%	-0.01%	-0.14%	-0.65%	-0.99%	57.61%
D&A (Non-Cash Add-back)	770K	1.37M	2.13M	2.23M	2.26M	2.43M	2.74M	3.55M	7.06M	7.04M
EBIT	32.39M	37.92M	53.79M	49.12M	33.89M	30.53M	27.07M	7.45M	-6.27M	-330K
Net Interest Income+	190K	141K	658K	1.86M	1.75M	-896K	335K	450K	511K	0
Interest Income	190K	141K	658K	1.86M	1.75M	314K	335K	450K	511K	0
Interest Expense	0	0	0	0	0	1.21M	0	0	0	0
Other Income/Expense	179K	441K	1.65M	2.95M	2.92M	419K	1.36M	894K	689K	943K
Pretax Income+	32.57M	37.92M	53.79M	49.12M	33.89M	30.95M	27.07M	7.45M	-6.27M	-587K
Pretax Margin %	0.14%	0.15%	0.2%	0.17%	0.12%	0.1%	0.1%	0.03%	-0.02%	-0%
Income Tax+	12M	14.11M	16.51M	11.38M	8.04M	7.03M	5.97M	2.31M	1.19M	5.68M
Effective Tax Rate %	0.63%	0.63%	0.69%	0.77%	0.76%	0.77%	0.78%	0.69%	1.19%	10.68%
Net Income+	20.57M	23.82M	37.28M	37.74M	25.85M	23.92M	21.1M	5.14M	-7.46M	-6.27M
Net Margin %	0.09%	0.1%	0.14%	0.13%	0.09%	0.08%	0.08%	0.02%	-0.03%	-0.03%
Net Income Growth %	0.18%	0.16%	0.57%	0.01%	-0.32%	-0.07%	-0.12%	-0.76%	-2.45%	0.16%
Net Income (Continuing)	20.57M	23.82M	37.28M	37.74M	25.85M	23.92M	21.1M	5.14M	-7.46M	-6.27M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.02	1.17	1.82	1.84	1.29	1.52	1.04	0.25	-0.37	-0.30
EPS Growth %	0.17%	0.15%	0.56%	0.01%	-0.3%	0.18%	-0.32%	-0.76%	-2.48%	0.19%
EPS (Basic)	1.02	1.18	1.83	1.84	1.29	1.53	1.05	0.25	-0.37	-0.30
Diluted Shares Outstanding	20.25M	20.38M	20.43M	20.49M	20.05M	20.12M	20.36M	20.34M	20.4M	20.6M
Basic Shares Outstanding	20.12M	20.23M	20.35M	20.46M	20.04M	20.06M	20.18M	20.27M	20.4M	20.6M
Dividend Payout Ratio	0.71%	0.65%	0.47%	0.58%	0.84%	0.95%	1.16%	4.77%	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	67.63M	81.78M	105.23M	126.43M	129.02M	161.19M	151M	130.43M	93.65M	78.87M
Cash & Short-Term Investments	37.64M	58.73M	77.94M	100.53M	103.76M	118.72M	111.08M	104.09M	55.3M	54.72M
Cash Only	37.64M	58.73M	77.94M	100.53M	103.76M	118.72M	111.08M	104.09M	55.3M	54.72M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.72M	1.81M	2.29M	2.54M	3.84M	2.59M	1.91M	1.74M	3.28M	2.32M
Days Sales Outstanding	2.68	2.65	3.06	3.27	4.94	3.11	2.55	2.48	4.37	3.73
Inventory	25.59M	20.23M	23.34M	21.37M	17.88M	34.42M	32.45M	19.02M	28.56M	16.2M
Days Inventory Outstanding	58.96	43.47	48.4	41.47	32.18	57.3	59.8	37.36	53.07	37.47
Other Current Assets	2.44M	1.02M	882K	1.41M	3.53M	4.5M	681K	4.72M	6.33M	5.63M
Total Non-Current Assets+	22.65M	31.02M	29.6M	28M	26.3M	26.31M	25.32M	39.57M	76.24M	69.83M
Property, Plant & Equipment	20.93M	30.16M	28.74M	27.14M	25.45M	25.45M	24.46M	26.18M	28.09M	29.82M
Fixed Asset Turnover	11.21x	8.26x	9.53x	10.44x	11.17x	11.93x	11.18x	9.80x	9.76x	7.61x
Goodwill	0	0	0	0	0	0	0	0	26.66M	26.66M
Intangible Assets	860K	860K	860K	860K	860K	860K	860K	5.86M	11.2M	13.35M
Long-Term Investments	-863K	0	0	0	25.52M	25.55M	24.27M	5M	5.3M	0
Other Non-Current Assets	863K	0	0	-28M	-26.3M	-26.31M	-25.32M	-5M	4.99M	0
Total Assets+	90.28M	112.81M	134.84M	154.43M	155.32M	187.5M	176.32M	170M	169.88M	148.7M
Asset Turnover	2.60x	2.21x	2.03x	1.84x	1.83x	1.62x	1.55x	1.51x	1.61x	1.53x
Asset Growth %	0.09%	0.25%	0.2%	0.15%	0.01%	0.21%	-0.06%	-0.04%	-0%	-0.12%
Total Current Liabilities+	7.08M	18.36M	18.11M	18.63M	24.34M	44.94M	33.2M	57.51M	72.16M	62.77M
Accounts Payable	5M	15.22M	15.27M	16.27M	19.66M	39.55M	27.5M	25.21M	37.02M	23.56M
Days Payables Outstanding	11.53	32.71	31.68	31.58	35.37	65.83	50.67	49.51	68.81	54.49
Short-Term Debt	0	0	0	0	0	0	0	0	459K	461K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	1000K	1000K
Other Current Liabilities	315K	1.06M	431K	613K	1.64M	1.83M	4.56M	30.74M	30.54M	36.66M
Current Ratio	9.55x	4.46x	5.81x	6.79x	5.30x	3.59x	4.55x	2.27x	1.30x	1.26x
Quick Ratio	5.93x	3.35x	4.52x	5.64x	4.57x	2.82x	3.57x	1.94x	0.90x	1.00x
Cash Conversion Cycle	50.11	13.41	19.78	13.16	1.75	-5.43	11.68	-9.67	-11.37	-13.29
Total Non-Current Liabilities+	5M	1.09M	996K	1.12M	970K	1.28M	936K	2.53M	995K	798K
Long-Term Debt	0	0	0	0	0	0	0	0	0	535K
Capital Lease Obligations	0	0	0	0	0	0	0	995K	995K	0
Deferred Tax Liabilities	5K	1.09M	996K	1.12M	970K	1.28M	936K	2.53M	0	263K
Other Non-Current Liabilities	0	0	0	0	0	0	0	-995K	0	0
Total Liabilities	7.08M	19.44M	19.11M	19.75M	25.31M	46.22M	34.13M	60.04M	73.15M	63.57M
Total Debt+	0	0	0	0	0	0	0	995K	1.45M	996K
Net Debt	-37.64M	-58.73M	-77.94M	-100.53M	-103.76M	-118.72M	-111.08M	-103.09M	-53.84M	-53.72M
Debt / Equity	-	-	-	-	-	-	-	0.01x	0.02x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	0.10x	15.47x	0.18x
Net Debt / EBITDA	-1.14x	-1.51x	-1.44x	-2.08x	-3.12x	-3.60x	-3.90x	-10.21x	-572.79x	-9.75x
Interest Coverage	-	-	-	-	-	25.23x	-	-	-	-
Total Equity+	83.19M	93.37M	115.73M	134.68M	130.01M	141.28M	142.19M	109.97M	96.73M	85.13M
Equity Growth %	0.1%	0.12%	0.24%	0.16%	-0.03%	0.09%	0.01%	-0.23%	-0.12%	-0.12%
Book Value per Share	4.11	4.58	5.66	6.57	6.48	7.02	6.98	5.41	4.74	4.13
Total Shareholders' Equity	83.19M	93.37M	115.73M	134.68M	130.01M	141.28M	142.19M	109.97M	96.73M	85.13M
Common Stock	20K	21K	21K	21K	20K	20K	21K	21K	21K	21K
Retained Earnings	78.3M	86.53M	106.32M	122.17M	126.18M	134.14M	130.5M	91.66M	71.56M	66.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-8.4M	-4.05M	-6.17M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	21.05M	47.2M	37.38M	45.14M	38.84M	40.08M	18.5M	27.8M	4.32M	4.72M
Operating CF Margin %	0.09%	0.19%	0.14%	0.16%	0.14%	0.13%	0.07%	0.11%	0.02%	0.02%
Operating CF Growth %	-0.34%	1.24%	-0.21%	0.21%	-0.14%	0.03%	-0.54%	0.5%	-0.84%	0.09%
Net Income	20.57M	23.82M	37.28M	37.74M	25.85M	30.6M	21.1M	233K	-7.46M	-6.27M
Depreciation & Amortization	770K	1.37M	2.13M	2.23M	2.26M	2.43M	2.74M	3.55M	7.06M	7.04M
Stock-Based Compensation	1.61M	1.94M	2.58M	3.1M	2.82M	3.31M	4.55M	6.62M	6.87M	-6.59M
Deferred Taxes	-23K	1.95M	-92K	125K	-151K	311K	-345K	-1.56M	292K	5.25M
Other Non-Cash Items	260K	421K	112K	85K	191K	130K	165K	5.05M	324K	1.56M
Working Capital Changes	-2.13M	17.71M	-4.63M	1.87M	7.87M	3.3M	-9.71M	13.92M	-2.76M	3.72M
Change in Receivables	-53K	-505K	-596K	-335K	-1.49M	1.13M	509K	-41K	-1.74M	601K
Change in Inventory	-518K	5.36M	-3.11M	1.97M	3.49M	-16.54M	1.97M	13.43M	-6.42M	12.35M
Change in Payables	-149K	10.22M	53K	1M	3.38M	19.89M	-12.05M	-2.29M	6.1M	-13.46M
Cash from Investing+	-4.49M	-10.6M	-703K	-620K	-2.31M	-2.43M	-1.75M	-10.26M	-40.67M	-5.11M
Capital Expenditures	-20.13M	-10.6M	-703K	-620K	-2.31M	-2.43M	-1.75M	-5.26M	-4.51M	-5.11M
CapEx % of Revenue	0.09%	0.04%	0%	0%	0.01%	0.01%	0.01%	0.02%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	15.64M	0	0	0	0	0	0	5M	0	0
Cash from Financing+	-14.54M	-15.51M	-17.47M	-21.93M	-33.3M	-22.69M	-24.38M	-24.54M	-12.44M	-181K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-14.68M	-15.51M	-17.47M	-21.93M	-21.8M	-22.69M	-24.38M	-24.54M	-12.44M	-181K
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	142K	0	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	923K	36.6M	36.68M	44.52M	36.53M	37.64M	16.75M	22.54M	-194K	-395K
FCF Margin %	0%	0.15%	0.13%	0.16%	0.13%	0.12%	0.06%	0.09%	-0%	-0%
FCF Growth %	-0.97%	38.65%	0%	0.21%	-0.18%	0.03%	-0.56%	0.35%	-1.01%	-1.04%
FCF per Share	0.05	1.80	1.79	2.17	1.82	1.87	0.82	1.11	-0.01	-0.02
FCF Conversion (FCF/Net Income)	1.02x	1.98x	1.00x	1.20x	1.50x	1.68x	0.88x	5.41x	-0.58x	-0.75x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	12.17M	11.37M	18.05M	11.05M	7.14M	10.02M	6.08M	4.31M	130K	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	25.93%	26.98%	35.66%	30.14%	19.53%	17.63%	14.89%	4.08%	-7.22%	-6.9%
Return on Invested Capital (ROIC)	56.9%	70.11%	107.97%	96.27%	76.93%	93.82%	71.86%	25.87%	-20.98%	-3.09%
Gross Margin	32.51%	31.83%	35.72%	33.63%	28.6%	27.77%	27.55%	27.68%	28.35%	30.46%
Net Margin	8.76%	9.56%	13.62%	13.32%	9.1%	7.88%	7.72%	2%	-2.72%	-2.76%
Debt / Equity	-	-	-	-	-	-	-	0.01x	0.02x	0.01x
Interest Coverage	-	-	-	-	-	25.23x	-	-	-	-
FCF Conversion	1.02x	1.98x	1.00x	1.20x	1.50x	1.68x	0.88x	5.41x	-0.58x	-0.75x
Revenue Growth	2.31%	6.18%	9.88%	3.51%	0.25%	6.85%	-9.94%	-6.16%	6.83%	-17.19%

Frequently Asked Questions

Growth & Financials

PetMed Express, Inc. (PETS) reported $195.0M in revenue for fiscal year 2025. This represents a 18% decrease from $238.3M in 2012.

PetMed Express, Inc. (PETS) saw revenue decline by 17.2% over the past year.

PetMed Express, Inc. (PETS) reported a net loss of $55.0M for fiscal year 2025.

Dividend & Returns

Yes, PetMed Express, Inc. (PETS) pays a dividend with a yield of 0.26%. This makes it attractive for income-focused investors.

PetMed Express, Inc. (PETS) has a return on equity (ROE) of -6.9%. Negative ROE indicates the company is unprofitable.

PetMed Express, Inc. (PETS) had negative free cash flow of $33.9M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

PetMed Express, Inc. (PETS) 10-Year Financial Performance & Capital Metrics

PETS • • Industrial / General

HealthcarePharmaceuticalsSpecialty Pharmaceuticals & DistributionPet Pharmaceuticals

Revenue $227M -17.2%
EBITDA $6M +5760.6%
Net Income -$6M +16.0%
EPS (Diluted) -0.30 +18.9%
Gross Margin 30.46% +7.4%
EBITDA Margin 2.43% +6976.4%
Operating Margin -0.67% +73.5%
Net Margin -2.76% -1.5%
ROE -6.9% +4.5%
ROIC -3.09% +85.3%
Debt/Equity 0.01 -22.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.8x book value
✓Efficient asset utilization: 1.5x turnover

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-0.11%

5Y-4.39%

3Y-6.02%

TTM-24.81%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-5613.71%

EPS CAGR

10Y-

5Y-

3Y-

TTM-4383.61%

ROCE

10Y Avg22.94%

5Y Avg7.43%

3Y Avg-1.05%

Latest-1.67%

Peer Comparison

Pet Pharmaceuticals

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PETSPetMed Express, Inc.	72.66M	3.40	-11.33	-17.19%	-28.22%	-127.77%		0.01

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	234.68M	249.18M	273.8M	283.42M	284.13M	303.58M	273.42M	256.58M	274.1M	226.97M
Revenue Growth %	0.02%	0.06%	0.1%	0.04%	0%	0.07%	-0.1%	-0.06%	0.07%	-0.17%
Cost of Goods Sold+	158.39M	169.86M	175.99M	188.1M	202.88M	219.27M	198.08M	185.84M	196.38M	157.84M
COGS % of Revenue	0.67%	0.68%	0.64%	0.66%	0.71%	0.72%	0.72%	0.72%	0.72%	0.7%
Gross Profit+	76.3M	79.31M	97.81M	95.31M	81.25M	84.32M	75.34M	71.01M	77.71M	69.14M
Gross Margin %	0.33%	0.32%	0.36%	0.34%	0.29%	0.28%	0.28%	0.28%	0.28%	0.3%
Gross Profit Growth %	0%	0.04%	0.23%	-0.03%	-0.15%	0.04%	-0.11%	-0.06%	0.09%	-0.11%
Operating Expenses+	43.91M	41.83M	45.67M	49.14M	50.27M	53.78M	49.63M	64.68M	84.67M	70.67M
OpEx % of Revenue	0.19%	0.17%	0.17%	0.17%	0.18%	0.18%	0.18%	0.25%	0.31%	0.31%
Selling, General & Admin	43.14M	40.46M	43.55M	46.91M	48.01M	49.93M	49.63M	68.9M	79.75M	62.43M
SG&A % of Revenue	0.18%	0.16%	0.16%	0.17%	0.17%	0.16%	0.18%	0.27%	0.29%	0.28%
Research & Development	0	0	0	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	770K	1.37M	2.13M	2.23M	2.26M	3.85M	0	-4.21M	4.92M	8.24M
Operating Income+	32.39M	37.48M	52.14M	46.17M	30.98M	30.53M	25.71M	6.55M	-6.96M	-1.53M
Operating Margin %	0.14%	0.15%	0.19%	0.16%	0.11%	0.1%	0.09%	0.03%	-0.03%	-0.01%
Operating Income Growth %	0.17%	0.16%	0.39%	-0.11%	-0.33%	-0.01%	-0.16%	-0.75%	-2.06%	0.78%
EBITDA+	33.16M	38.85M	54.26M	48.4M	33.23M	32.96M	28.45M	10.1M	94K	5.51M
EBITDA Margin %	0.14%	0.16%	0.2%	0.17%	0.12%	0.11%	0.1%	0.04%	0%	0.02%
EBITDA Growth %	0.17%	0.17%	0.4%	-0.11%	-0.31%	-0.01%	-0.14%	-0.65%	-0.99%	57.61%
D&A (Non-Cash Add-back)	770K	1.37M	2.13M	2.23M	2.26M	2.43M	2.74M	3.55M	7.06M	7.04M
EBIT	32.39M	37.92M	53.79M	49.12M	33.89M	30.53M	27.07M	7.45M	-6.27M	-330K
Net Interest Income+	190K	141K	658K	1.86M	1.75M	-896K	335K	450K	511K	0
Interest Income	190K	141K	658K	1.86M	1.75M	314K	335K	450K	511K	0
Interest Expense	0	0	0	0	0	1.21M	0	0	0	0
Other Income/Expense	179K	441K	1.65M	2.95M	2.92M	419K	1.36M	894K	689K	943K
Pretax Income+	32.57M	37.92M	53.79M	49.12M	33.89M	30.95M	27.07M	7.45M	-6.27M	-587K
Pretax Margin %	0.14%	0.15%	0.2%	0.17%	0.12%	0.1%	0.1%	0.03%	-0.02%	-0%
Income Tax+	12M	14.11M	16.51M	11.38M	8.04M	7.03M	5.97M	2.31M	1.19M	5.68M
Effective Tax Rate %	0.63%	0.63%	0.69%	0.77%	0.76%	0.77%	0.78%	0.69%	1.19%	10.68%
Net Income+	20.57M	23.82M	37.28M	37.74M	25.85M	23.92M	21.1M	5.14M	-7.46M	-6.27M
Net Margin %	0.09%	0.1%	0.14%	0.13%	0.09%	0.08%	0.08%	0.02%	-0.03%	-0.03%
Net Income Growth %	0.18%	0.16%	0.57%	0.01%	-0.32%	-0.07%	-0.12%	-0.76%	-2.45%	0.16%
Net Income (Continuing)	20.57M	23.82M	37.28M	37.74M	25.85M	23.92M	21.1M	5.14M	-7.46M	-6.27M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.02	1.17	1.82	1.84	1.29	1.52	1.04	0.25	-0.37	-0.30
EPS Growth %	0.17%	0.15%	0.56%	0.01%	-0.3%	0.18%	-0.32%	-0.76%	-2.48%	0.19%
EPS (Basic)	1.02	1.18	1.83	1.84	1.29	1.53	1.05	0.25	-0.37	-0.30
Diluted Shares Outstanding	20.25M	20.38M	20.43M	20.49M	20.05M	20.12M	20.36M	20.34M	20.4M	20.6M
Basic Shares Outstanding	20.12M	20.23M	20.35M	20.46M	20.04M	20.06M	20.18M	20.27M	20.4M	20.6M
Dividend Payout Ratio	0.71%	0.65%	0.47%	0.58%	0.84%	0.95%	1.16%	4.77%	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	67.63M	81.78M	105.23M	126.43M	129.02M	161.19M	151M	130.43M	93.65M	78.87M
Cash & Short-Term Investments	37.64M	58.73M	77.94M	100.53M	103.76M	118.72M	111.08M	104.09M	55.3M	54.72M
Cash Only	37.64M	58.73M	77.94M	100.53M	103.76M	118.72M	111.08M	104.09M	55.3M	54.72M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.72M	1.81M	2.29M	2.54M	3.84M	2.59M	1.91M	1.74M	3.28M	2.32M
Days Sales Outstanding	2.68	2.65	3.06	3.27	4.94	3.11	2.55	2.48	4.37	3.73
Inventory	25.59M	20.23M	23.34M	21.37M	17.88M	34.42M	32.45M	19.02M	28.56M	16.2M
Days Inventory Outstanding	58.96	43.47	48.4	41.47	32.18	57.3	59.8	37.36	53.07	37.47
Other Current Assets	2.44M	1.02M	882K	1.41M	3.53M	4.5M	681K	4.72M	6.33M	5.63M
Total Non-Current Assets+	22.65M	31.02M	29.6M	28M	26.3M	26.31M	25.32M	39.57M	76.24M	69.83M
Property, Plant & Equipment	20.93M	30.16M	28.74M	27.14M	25.45M	25.45M	24.46M	26.18M	28.09M	29.82M
Fixed Asset Turnover	11.21x	8.26x	9.53x	10.44x	11.17x	11.93x	11.18x	9.80x	9.76x	7.61x
Goodwill	0	0	0	0	0	0	0	0	26.66M	26.66M
Intangible Assets	860K	860K	860K	860K	860K	860K	860K	5.86M	11.2M	13.35M
Long-Term Investments	-863K	0	0	0	25.52M	25.55M	24.27M	5M	5.3M	0
Other Non-Current Assets	863K	0	0	-28M	-26.3M	-26.31M	-25.32M	-5M	4.99M	0
Total Assets+	90.28M	112.81M	134.84M	154.43M	155.32M	187.5M	176.32M	170M	169.88M	148.7M
Asset Turnover	2.60x	2.21x	2.03x	1.84x	1.83x	1.62x	1.55x	1.51x	1.61x	1.53x
Asset Growth %	0.09%	0.25%	0.2%	0.15%	0.01%	0.21%	-0.06%	-0.04%	-0%	-0.12%
Total Current Liabilities+	7.08M	18.36M	18.11M	18.63M	24.34M	44.94M	33.2M	57.51M	72.16M	62.77M
Accounts Payable	5M	15.22M	15.27M	16.27M	19.66M	39.55M	27.5M	25.21M	37.02M	23.56M
Days Payables Outstanding	11.53	32.71	31.68	31.58	35.37	65.83	50.67	49.51	68.81	54.49
Short-Term Debt	0	0	0	0	0	0	0	0	459K	461K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	1000K	1000K
Other Current Liabilities	315K	1.06M	431K	613K	1.64M	1.83M	4.56M	30.74M	30.54M	36.66M
Current Ratio	9.55x	4.46x	5.81x	6.79x	5.30x	3.59x	4.55x	2.27x	1.30x	1.26x
Quick Ratio	5.93x	3.35x	4.52x	5.64x	4.57x	2.82x	3.57x	1.94x	0.90x	1.00x
Cash Conversion Cycle	50.11	13.41	19.78	13.16	1.75	-5.43	11.68	-9.67	-11.37	-13.29
Total Non-Current Liabilities+	5M	1.09M	996K	1.12M	970K	1.28M	936K	2.53M	995K	798K
Long-Term Debt	0	0	0	0	0	0	0	0	0	535K
Capital Lease Obligations	0	0	0	0	0	0	0	995K	995K	0
Deferred Tax Liabilities	5K	1.09M	996K	1.12M	970K	1.28M	936K	2.53M	0	263K
Other Non-Current Liabilities	0	0	0	0	0	0	0	-995K	0	0
Total Liabilities	7.08M	19.44M	19.11M	19.75M	25.31M	46.22M	34.13M	60.04M	73.15M	63.57M
Total Debt+	0	0	0	0	0	0	0	995K	1.45M	996K
Net Debt	-37.64M	-58.73M	-77.94M	-100.53M	-103.76M	-118.72M	-111.08M	-103.09M	-53.84M	-53.72M
Debt / Equity	-	-	-	-	-	-	-	0.01x	0.02x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	0.10x	15.47x	0.18x
Net Debt / EBITDA	-1.14x	-1.51x	-1.44x	-2.08x	-3.12x	-3.60x	-3.90x	-10.21x	-572.79x	-9.75x
Interest Coverage	-	-	-	-	-	25.23x	-	-	-	-
Total Equity+	83.19M	93.37M	115.73M	134.68M	130.01M	141.28M	142.19M	109.97M	96.73M	85.13M
Equity Growth %	0.1%	0.12%	0.24%	0.16%	-0.03%	0.09%	0.01%	-0.23%	-0.12%	-0.12%
Book Value per Share	4.11	4.58	5.66	6.57	6.48	7.02	6.98	5.41	4.74	4.13
Total Shareholders' Equity	83.19M	93.37M	115.73M	134.68M	130.01M	141.28M	142.19M	109.97M	96.73M	85.13M
Common Stock	20K	21K	21K	21K	20K	20K	21K	21K	21K	21K
Retained Earnings	78.3M	86.53M	106.32M	122.17M	126.18M	134.14M	130.5M	91.66M	71.56M	66.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-8.4M	-4.05M	-6.17M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	21.05M	47.2M	37.38M	45.14M	38.84M	40.08M	18.5M	27.8M	4.32M	4.72M
Operating CF Margin %	0.09%	0.19%	0.14%	0.16%	0.14%	0.13%	0.07%	0.11%	0.02%	0.02%
Operating CF Growth %	-0.34%	1.24%	-0.21%	0.21%	-0.14%	0.03%	-0.54%	0.5%	-0.84%	0.09%
Net Income	20.57M	23.82M	37.28M	37.74M	25.85M	30.6M	21.1M	233K	-7.46M	-6.27M
Depreciation & Amortization	770K	1.37M	2.13M	2.23M	2.26M	2.43M	2.74M	3.55M	7.06M	7.04M
Stock-Based Compensation	1.61M	1.94M	2.58M	3.1M	2.82M	3.31M	4.55M	6.62M	6.87M	-6.59M
Deferred Taxes	-23K	1.95M	-92K	125K	-151K	311K	-345K	-1.56M	292K	5.25M
Other Non-Cash Items	260K	421K	112K	85K	191K	130K	165K	5.05M	324K	1.56M
Working Capital Changes	-2.13M	17.71M	-4.63M	1.87M	7.87M	3.3M	-9.71M	13.92M	-2.76M	3.72M
Change in Receivables	-53K	-505K	-596K	-335K	-1.49M	1.13M	509K	-41K	-1.74M	601K
Change in Inventory	-518K	5.36M	-3.11M	1.97M	3.49M	-16.54M	1.97M	13.43M	-6.42M	12.35M
Change in Payables	-149K	10.22M	53K	1M	3.38M	19.89M	-12.05M	-2.29M	6.1M	-13.46M
Cash from Investing+	-4.49M	-10.6M	-703K	-620K	-2.31M	-2.43M	-1.75M	-10.26M	-40.67M	-5.11M
Capital Expenditures	-20.13M	-10.6M	-703K	-620K	-2.31M	-2.43M	-1.75M	-5.26M	-4.51M	-5.11M
CapEx % of Revenue	0.09%	0.04%	0%	0%	0.01%	0.01%	0.01%	0.02%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	15.64M	0	0	0	0	0	0	5M	0	0
Cash from Financing+	-14.54M	-15.51M	-17.47M	-21.93M	-33.3M	-22.69M	-24.38M	-24.54M	-12.44M	-181K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-14.68M	-15.51M	-17.47M	-21.93M	-21.8M	-22.69M	-24.38M	-24.54M	-12.44M	-181K
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	142K	0	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	923K	36.6M	36.68M	44.52M	36.53M	37.64M	16.75M	22.54M	-194K	-395K
FCF Margin %	0%	0.15%	0.13%	0.16%	0.13%	0.12%	0.06%	0.09%	-0%	-0%
FCF Growth %	-0.97%	38.65%	0%	0.21%	-0.18%	0.03%	-0.56%	0.35%	-1.01%	-1.04%
FCF per Share	0.05	1.80	1.79	2.17	1.82	1.87	0.82	1.11	-0.01	-0.02
FCF Conversion (FCF/Net Income)	1.02x	1.98x	1.00x	1.20x	1.50x	1.68x	0.88x	5.41x	-0.58x	-0.75x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	12.17M	11.37M	18.05M	11.05M	7.14M	10.02M	6.08M	4.31M	130K	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	25.93%	26.98%	35.66%	30.14%	19.53%	17.63%	14.89%	4.08%	-7.22%	-6.9%
Return on Invested Capital (ROIC)	56.9%	70.11%	107.97%	96.27%	76.93%	93.82%	71.86%	25.87%	-20.98%	-3.09%
Gross Margin	32.51%	31.83%	35.72%	33.63%	28.6%	27.77%	27.55%	27.68%	28.35%	30.46%
Net Margin	8.76%	9.56%	13.62%	13.32%	9.1%	7.88%	7.72%	2%	-2.72%	-2.76%
Debt / Equity	-	-	-	-	-	-	-	0.01x	0.02x	0.01x
Interest Coverage	-	-	-	-	-	25.23x	-	-	-	-
FCF Conversion	1.02x	1.98x	1.00x	1.20x	1.50x	1.68x	0.88x	5.41x	-0.58x	-0.75x
Revenue Growth	2.31%	6.18%	9.88%	3.51%	0.25%	6.85%	-9.94%	-6.16%	6.83%	-17.19%

Frequently Asked Questions

Growth & Financials

PetMed Express, Inc. (PETS) reported $195.0M in revenue for fiscal year 2025. This represents a 18% decrease from $238.3M in 2012.

PetMed Express, Inc. (PETS) saw revenue decline by 17.2% over the past year.

PetMed Express, Inc. (PETS) reported a net loss of $55.0M for fiscal year 2025.

Dividend & Returns

Yes, PetMed Express, Inc. (PETS) pays a dividend with a yield of 0.26%. This makes it attractive for income-focused investors.

PetMed Express, Inc. (PETS) has a return on equity (ROE) of -6.9%. Negative ROE indicates the company is unprofitable.

PetMed Express, Inc. (PETS) had negative free cash flow of $33.9M in fiscal year 2025, likely due to heavy capital investments.